New AI Tool Allows Remote Assessment of Parkinson’s Symptoms in Minutes, US

Date:

New AI Tool Allows Remote Assessment of Parkinson’s Symptoms in Minutes

Researchers at the University of Rochester have developed an artificial intelligence (AI) tool that enables individuals with Parkinson’s disease to remotely assess the severity of their symptoms within minutes. This groundbreaking tool, described in a study published in npj Digital Medicine, requires users to tap their fingers ten times in front of a webcam, which helps evaluate their motor performance on a scale of 0-4.

Traditionally, doctors have patients perform simple motor tasks to assess movement disorders and determine their severity, using guidelines such as the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). However, the new AI model developed by the University of Rochester provides a rapid assessment based on these guidelines. It generates computational metrics, including speed, amplitude, frequency, and period, which are interpretable, standardized, repeatable, and consistent with medical guidebooks. It further uses these attributes to classify the severity of tremors.

To validate the tool’s accuracy, the research team had 250 global participants with Parkinson’s disease perform the finger-tapping task. The AI system’s ratings were then compared with those of three neurologists and three primary care physicians. Although the expert neurologists performed slightly better than the AI model, the AI model outperformed the primary care physicians who had UPDRS certification.

One of the significant implications highlighted by Ehsan Hoque, an associate professor at Rochester’s Department of Computer Science and co-director of the Rochester Human-Computer Interaction Laboratory, is the potential to improve healthcare accessibility and equity for patients who face challenges in accessing neurologists, securing appointments, and traveling to hospitals.

See also  Nigerian Startups Shine at GITEX Africa 2024 Expo

The lead researcher of the study, Md. Saiful Islam, a Google PhD fellow and a graduate student in computer science advised by Hoque, emphasized that this AI method can be applied to other motor tasks, opening the door to evaluating different types of movement disorders such as ataxia and Huntington’s disease. Although the new Parkinson’s assessment tool is available online, the researchers caution that it should not be considered as a definitive measure of the presence or severity of the disease without a physician’s input, as it is still an emerging technology.

The findings of this study mark a significant step towards integrating AI into healthcare, enabling remote assessments and expanding access to necessary medical evaluations. By leveraging technology, individuals with Parkinson’s disease can conveniently and efficiently monitor their symptoms, eliminating the need for frequent visits to a clinic. As AI continues to advance, it holds great promise for improving health equity and accessibility across various medical conditions.

Frequently Asked Questions (FAQs) Related to the Above News

What is the AI tool developed by researchers at the University of Rochester?

The AI tool developed by researchers at the University of Rochester is a tool that enables individuals with Parkinson's disease to assess the severity of their symptoms remotely and within minutes. It only requires users to tap their fingers in front of a webcam ten times to evaluate their motor performance on a scale of 0-4.

How does the AI model assess the severity of Parkinson's symptoms?

The AI model assesses the severity of Parkinson's symptoms by using computational metrics that align with medical guidebooks, such as the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS). These metrics include attributes like speed, amplitude, frequency, and period, ensuring interpretability, standardization, repeatability, and consistency.

How was the AI model validated?

The AI model was validated by having 250 individuals with Parkinson's disease perform the finger-tapping task. The AI system's ratings were then compared with those provided by expert neurologists and primary care physicians who had UPDRS certification.

How does the AI tool improve accessibility for patients?

The AI tool improves accessibility for patients by providing a means of remote assessment, reducing the need for in-person consultations. This is especially beneficial for patients who face difficulties in accessing neurologists, securing appointments, and traveling to hospitals.

Can the AI model be used to assess other movement disorders?

Yes, the researchers at the University of Rochester state that their method can be adapted to evaluate other motor tasks, thereby expanding its utility to assess other types of movement disorders such as ataxia and Huntington's disease.

Is the AI tool a definitive measure of the presence or severity of Parkinson's disease?

No, the researchers caution that the AI tool should not be considered a definitive measure of the presence or severity of Parkinson's disease on its own, without input from a physician. It should be used as a tool to assist in assessments, but not as a standalone diagnostic tool.

Please note that the FAQs provided on this page are based on the news article published. While we strive to provide accurate and up-to-date information, it is always recommended to consult relevant authorities or professionals before making any decisions or taking action based on the FAQs or the news article.

Share post:

Subscribe

Popular

More like this
Related

Obama’s Techno-Optimism Shifts as Democrats Navigate Changing Tech Landscape

Explore the evolution of tech policy from Obama's optimism to Harris's vision at the Democratic National Convention. What's next for Democrats in tech?

Tech Evolution: From Obama’s Optimism to Harris’s Vision

Explore the evolution of tech policy from Obama's optimism to Harris's vision at the Democratic National Convention. What's next for Democrats in tech?

Tonix Pharmaceuticals TNXP Shares Fall 14.61% After Q2 Earnings Report

Tonix Pharmaceuticals TNXP shares decline 14.61% post-Q2 earnings report. Evaluate investment strategy based on company updates and market dynamics.

The Future of Good Jobs: Why College Degrees are Essential through 2031

Discover the future of good jobs through 2031 and why college degrees are essential. Learn more about job projections and AI's influence.